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Adolescent HIV Pre-Exposure Prophylaxis Prescribing Practices Among Family 
Medicine Physicians: Limited Immediate Uptake 
Emma T Cooper; Steven A Elsesser, MD; Amy Cunningham, PhD, MPH; Marshal N 
Miller, MD* 
 
Introduction: In the United States, individuals aged 13-24 made up 21% of new HIV 
infections in 2016. In 2018, the FDA approved tenofovir/emtricitabine as HIV pre-
exposure prophylaxis (PrEP) for adolescents aged 15-17. In 2019, we 
examined adolescent PrEP prescribing practices among family medicine physicians at an 
academic family medicine practice.  
Methods: Physicians were invited to complete an online questionnaire 
assessing PrEP knowledge, attitudes, and prescribing 
practices. Differences in PrEP knowledge and attitudes among providers who 
prescribe PrEP to adolescents versus those who do not were examined using independent 
samples t-tests.  
Results: 50 out of 99 surveys were completed. Respondents were 90% White, 84% 
heterosexual, 50% attendings, 50% residents/fellows, and 2% HIV 
specialists. All respondents had heard of PrEP before the survey, 76% had 
prescribed PrEP and 70% reported being aware of the FDA approval of PrEP for 
adolescents. While 86% reported treating patients aged 15-17, only 6% 
reported having prescribed PrEP to this demographic. Physicians who 
SI/PHR Abstract 
reported prescribing PrEP to adolescents reported greater comfort assessing for 
indications for PrEP, t(48)= -2.23, p < 0.05, greater PrEP knowledge, t(47)= -3.34, p < 
0.005, and felt PrEP was safer, t(48)= -2.09, p < 0.05, compared to physicians who had 
not.  
Conclusion: Despite universal awareness of PrEP, high rates of prescribing to adults, and 
awareness of FDA approval of PrEP for adolescents, PrEP prescribing to adolescents in 
our sample remains limited. Differences between providers who have and have not 
prescribed PrEP to adolescents suggest targeted training may boost prescribing to this 
demographic.  
